Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-06-21
DOI
10.1093/jac/dkac186
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epidemiology of extended-spectrum β-lactamase and metallo-β-lactamase-producing Escherichia coli in South Asia
- (2021) Kamrul Islam et al. Future Microbiology
- High Prevalence of Extended-Spectrum Beta-Lactamases in Escherichia coli Strains Collected From Strictly Defined Community-Acquired Urinary Tract Infections in Adults in China: A Multicenter Prospective Clinical Microbiological and Molecular Study
- (2021) Peiyao Jia et al. Frontiers in Microbiology
- Antimicrobial resistance of gram-negative bacteria: A six-year longitudinal study in a hospital in Saudi Arabia
- (2020) Jaffar A. Al-Tawfiq et al. Journal of Infection and Public Health
- Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model
- (2020) Thomas P Lodise et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Urinary piperacillin/tazobactam pharmacokinetics in-vitro to determine the pharmacodynamic breakpoint for resistant Enterobacteriacae
- (2019) M. Gould et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study
- (2019) Zafer Tandogdu et al. WORLD JOURNAL OF UROLOGY
- Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase–Producing Organisms?
- (2019) Sima L Sharara et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
- (2018) Jianguo Li et al. CTS-Clinical and Translational Science
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance
- (2018) Patrick N. A. Harris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- MIC-based dose adjustment: facts and fables
- (2017) Johan W Mouton et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Global epidemiology of CTX-M β-lactamases: temporal and geographical shifts in genotype
- (2017) Edward R. Bevan et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Beta-lactamase database (BLDB) – structure and function
- (2017) Thierry Naas et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy
- (2016) Fekade Bruck Sime et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients
- (2016) Francesca Mattioli et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of different renal function on antibacterial effects of piperacillin againstPseudomonas aeruginosaevaluated via the hollow-fibre infection model and mechanism-based modelling
- (2016) Phillip J. Bergen et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Targeted benefits of prolonged-infusion piperacillin-tazobactam in anin vitroinfection model ofPseudomonas aeruginosa
- (2016) S. Zelenitsky et al. JOURNAL OF CHEMOTHERAPY
- Impact of infection with extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs
- (2016) J.A. Maslikowska et al. JOURNAL OF HOSPITAL INFECTION
- Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
- (2016) Tat Ming Ng et al. PLoS One
- Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes
- (2015) Tawanda Gumbo et al. CLINICAL INFECTIOUS DISEASES
- Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003–2013
- (2015) Zafer Tandoğdu et al. WORLD JOURNAL OF UROLOGY
- Interaction of Drug- and Granulocyte-Mediated Killing of Pseudomonas aeruginosa in a Murine Pneumonia Model
- (2014) G. L. Drusano et al. JOURNAL OF INFECTIOUS DISEASES
- Correlations of Antibiotic Use and Carbapenem Resistance in Enterobacteriaceae
- (2013) Milena McLaughlin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Inoculum Effect on the Efficacies of Amoxicillin-Clavulanate, Piperacillin-Tazobactam, and Imipenem against Extended-Spectrum β-Lactamase (ESBL)-Producing and Non-ESBL-Producing Escherichia coli in an Experimental Murine Sepsis Model
- (2013) F. Docobo-Pérez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study
- (2012) Mitchell M Levy et al. LANCET INFECTIOUS DISEASES
- Three Decades of -Lactamase Inhibitors
- (2010) S. M. Drawz et al. CLINICAL MICROBIOLOGY REVIEWS
- Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
- (2008) Johann DD Pitout et al. LANCET INFECTIOUS DISEASES
- Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances
- (2008) Irith Wiegand et al. Nature Protocols
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More